SALT LAKE CITY, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food
and Drug Administration (“FDA”) has extended the review period for the New Drug Application (“NDA”) for TLANDO, the Company’s oral
testosterone product candidate for the proposed indication of testosterone replacement therapy (“TRT”) in adult males for
conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. The FDA has assigned a new
Prescription Drug User Fee Act (“PDUFA”) goal date of May 8, 2018.
The FDA extended the action goal date to allow time to review additional data analyses recently submitted as an
amendment to the NDA in response to the FDA’s Information Requests. Upon preliminary review of the amendment by the FDA, the
submission of the requested information has been determined to represent a Major Amendment to the NDA resulting in an extension of
the PDUFA goal date by three months to provide time for a full review.
The previously scheduled Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) meeting on January 10, 2018 to
discuss the NDA for TLANDO remains unchanged.
“We believe TLANDO addresses a significant unmet medical need for men with hypogonadism and we will continue to work closely
with the FDA throughout the review process," said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of
Lipocine.
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's
and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three
development programs TLANDO, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone
undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the
primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review. LPCN 1111, a novel
oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with
potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral
hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan
drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please
visit www.lipocine.com.
Forward-Looking Statements
This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine’s product
candidates and related clinical trials and the FDA review process relating to its product candidates, the expected timing of the
FDA review process related to our resubmitted NDA, the path to approvability by the FDA of Lipocine’s development programs, the
potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such
forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve
any of our products, the risk that Bone, Reproductive, Urologic and Drug Advisory Committee (“BRUDAC”) may make a negative
recommendation to the Commissioner of the FDA with respect to TLANDO, risks related to our products, expected product benefits not
being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements,
risks related to the FDA approval process including that the FDA will determine there are deficiencies in our resubmitted NDA, the
receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the
manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including,
without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release,
except as required by law.
CONTACT:
Morgan Brown
Executive Vice President & Chief Financial Officer
Phone: (801) 994-7383
mb@lipocine.com
Investors:
Hans Vitzhum
Phone: (646) 597-6979
hans@lifesciadvisors.com
